|
**Overview**: Herpes Simplex Virus 1 Antibodies Panel**Introduction**: The Herpes Simplex Virus 1 Antibodies Panel is a diagnostic tool designed to screen for HSV-1 infection using serum samples. In India, HSV-1 seroprevalence is high (~70-90 percent in adults), causing orolabial herpes, but also encephalitis in neonates/immunocompromised. High morbidity from under-testing in rural/low-SES patients with recurrent oral ulcers or suspected encephalitis, limited labs, delayed acyclovir leading to severe neurological sequelae. Per microbiology practices aligned with ICMR and IDSP guidelines, the test employs immunoassay for HSV-1 IgG and IgM over 1-2 days with high specificity, valuable for diagnosing primary/recurrent infection or past exposure. This diagnostic falls under viral screening and targets patients with oral lesions, encephalitis suspicion, or pregnancy risk, addressing accurate detection to guide acyclovir therapy or counseling. With elevated morbidity due to underdiagnosis, the test supports public health efforts by enabling precise HSV-1 assessment and reducing complications. Its serum-based approach ensures reliable serology.**Other Names**: HSV 1 Ab Pnl.**FDA Status**: FDA approved, CLIA certified for immunology/microbiology, compliant with 2025 standards.**Historical Milestone**: HSV-1 IgG/IgM standard; in India, used in neurology clinics.**Purpose**: The test assesses 2 parameters including HSV-1 IgG to guide HSV-1 infection screening, detect acute/past infection, inform therapy.**Test Parameters**: 1. HSV-1 IgG, 2. HSV-1 IgM.**Pretest Condition**: No fasting required; patients should report oral ulcers or neurological symptoms.**Specimen**: 3 mL serum in 1 SST, transported within specified times to maintain sample viability.**Sample Stability at Room Temperature**: 8 hours with proper handling to preserve analyte integrity, ensuring reliable test performance.**Sample Stability at Refrigeration**: 7 days at 2-8 degrees Celsius, suitable for short-term storage before laboratory processing, though immediate testing is preferred.**Sample Stability at Frozen**: 6 months at -20 degrees Celsius, allowing long-term storage for retesting, though freezing may affect some analytes.**Medical History**: Patients should provide details on lesion recurrence, encephalitis symptoms.**Consent**: Written informed consent is required, detailing the test's purpose, potential risks of untreated HSV including encephalitis, benefits of detection, and minimal discomfort from venipuncture.**Procedural Considerations**: The test involves sample processing using immunoassay by trained personnel to ensure sterile technique, avoid hemolysis, and interpret results within 1-2 days using provided controls. Laboratories must maintain a controlled environment, adhere to quality assurance protocols.**Factors Affecting Result Accuracy**: Delays beyond stability periods, improper storage conditions, hemolysis, or cross-reactivity can affect results. Correlation with clinical evaluation or additional testing is recommended to confirm findings.**Clinical Significance**: Positive IgM indicates acute infection; IgG positive past exposure, necessitating specialist input.**Specialist Consultation**: Infectious disease specialists or neurologists should be consulted for management.**Additional Supporting Tests**: HSV PCR for confirmation.**Test Limitations**: IgM may be false-positive; comprehensive approach required.**References**: Indian Journal of Medical Microbiology 2024, HSV Studies India 2023. |
